Project Grant R01CA311340
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant totaling $546,842 (awarded July 1, 2026; completion June 30, 2031) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct research on germline determinants of tumor development and treatment response. The project will deliver a meta-analysis framework and functional validation studies identifying how inherited germline...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $745,458 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period July 1, 2026 through June 30, 2031. The award funds development and implementation of the PERSON Intervention, an innovative digital health solution designed to facilitate person-centered communication between oncology patients and clinicians. The intervention...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $3.2 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning August 1, 2025, and concluding July 31, 2029. This research initiative investigates the mechanisms of extrachromosomal DNA (ecDNA) segregation and repair in cancer cells, with emphasis on understanding how ecDNA's circular topology contributes to tumor progression...
- Federal Project Grant Award Summary The National Cancer Institute awarded $292,028 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) beginning August 1, 2025, and concluding July 31, 2030. This five-year Project Grant supports research investigating genome instability associated with focal oncogene amplification (OA) and the development of therapeutic strategies to address treatment-resistant cancers. The research deliverables include...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $444,590 under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, with a completion date of May 31, 2028. This grant supports a comprehensive evaluation of genetic and epigenetic determinants that influence treatment response in patients with advanced myeloproliferative neoplasms (MPNs)—specifically accelerated-phase and blast-phase...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $421,685 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period June 1, 2026, through May 31, 2028. This research initiative addresses methodological gaps in risk assessment for rare cancer patients by developing advanced statistical frameworks that leverage information from multiple data sources. The project will deliver two novel transfer-learning-based...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...
- Federal Grant Award Summary The National Cancer Institute awarded a $671,252 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms of anti-tumor immunity mediated by immune cell triads. The research project, effective from July 1, 2026 through June 30, 2031, will advance fundamental understanding of how CD4 T cells, CD8 T cells, and dendritic cells must spatially organize and interact within tumors...
The National Cancer Institute awarded a Project Grant totaling $366,662 to the Sloan-Kettering Institute for Cancer Research, effective July 1, 2026 through June 30, 2030, under the Cancer Cause and Prevention Research program (CFDA 93.393). This grant funds the development of novel statistical methodologies for conducting mediation analysis using epidemiologic data from multiple incomplete data sources. The research addresses a critical gap in current analytical capabilities by creating statistical frameworks that can estimate mediation effects when the three key variables (exposure, mediator, and outcome) are distributed across separate datasets rather than contained within a single unified dataset. This methodological advancement will enable epidemiologists to conduct rigorous mediation analysis in real-world research scenarios where complete joint information on all relevant variables is not available from any single source. The project comprises three integrated research aims: Aim 1 develops a semiparametric framework for estimating regression parameters without requiring parametric distribution assumptions; Aim 2 extends this methodology to account for heterogeneity in covariate, mediator, and exposure distributions across multiple data sources; and Aim 3 introduces high-dimensional mediation analysis methods building on Aims 1 and 2. These deliverables will provide the epidemiologic research community with practical statistical tools applicable to diverse data configurations and combinations, enhancing the capacity to identify mechanisms explaining established exposure-outcome relationships in cancer research and related health domains.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $366.7k | 6/30/26 |